Trial watch: Dendritic cell-based anticancer immunotherapy

Trial watch: Dendritic cell-based anticancer immunotherapy

Dendritic cell (DC)-based vaccines against cancer have been extensively developed over the past two decades. Typically DC-based cancer immunotherapy entails loading patient-derived DCs with an appropriate source of tumor-associated antigens (TAAs) and efficient DC stimulation through a so-called “ma...

Full description

Bibliographic Details
Main Authors: Abhishek D. Garg, Monica Vara Perez, Marco Schaaf, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi
Format: Article
Language:English
Published: Taylor & Francis Group 2017-07-01
Series:OncoImmunology
Subjects:
antigen cross-presentation
damps
immune-checkpoint blockers
plasmacytoid dendritic cells
tlr signaling
tumor-infiltrating lymphocytes
Online Access:http://dx.doi.org/10.1080/2162402X.2017.1328341

Internet

http://dx.doi.org/10.1080/2162402X.2017.1328341

Similar Items